سعر ريفامبين 150مجم 10 كبسول 2025

Rifampicin 150 mg oral capsules, pack of 10, marketed in Egypt by Debeiky.

• Treatment of all forms of tuberculosis (in combination regimens)Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)
• Treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx (not for meningococcal infection)Population: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)

• Gastrointestinal: heartburn, epigastric distress, anorexia, nausea, vomiting, diarrhea, cramps; pseudomembranous colitis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic enzyme/bilirubin elevations and hepatitis; thrombocytopenia (mainly with high-dose intermittent therapy); flu-like syndrome with intermittent dosing.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to rifampin, any component or any rifamycin.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant ritonavir-boosted saquinavir, atazanavir, darunavir, fosamprenavir, saquinavir, tipranavir, cabotegravir, fostemsavir, lenacapavir, praziquantel or lurasidone.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hepatotoxicity (hepatocellular, cholestatic, mixed) up to fulminant liver failure; monitor, especially with other hepatotoxic drugs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Systemic hypersensitivity reactions and severe cutaneous adverse reactions (SJS, TEN, AGEP, DRESS): discontinue immediately.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Vitamin K-dependent coagulation disorders and bleeding; thrombotic microangiopathy; pulmonary toxicity (interstitial lung disease).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CYP450/UGT/P-gp substrates (e.g. warfarin, oral contraceptives, corticosteroids, cyclosporine, tacrolimus, methadone, digoxin)Rifampin is a potent inducer of CYP1A2, 2B6, 2C8, 2C9, 2C19, 3A4, UGT and P-gp and decreases exposure of many co-administered drugs.DailyMed (U.S. National Library of Medicine)
• Isoniazid, halothaneIncreased hepatotoxicity potential; avoid halothane; monitor closely with isoniazid.DailyMed (U.S. National Library of Medicine)
• AntacidsMay reduce rifampin absorption; give rifampin at least 1 hour before antacids.DailyMed (U.S. National Library of Medicine)

• Crosses the placenta; no adequate controlled studies; decades of data have not established an association with major birth defects. Use only if benefit outweighs risk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Decide whether to discontinue nursing or the drug, considering tumorigenicity shown in animal studies.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Rifampicin: Inhibits bacterial DNA-dependent RNA polymerase (does not inhibit the mammalian enzyme).